Takeaway

• The vast majority of eligible patients with type 2 diabetes (T2D) at very high cardiovascular risk are not being prescribed sodium-glucose cotransporter-2 inhibitors (SGLT2i), as current guidelines advise.

Why this matters

• The Dutch College of General Practitioners (GP) published revised T2D guidelines in November 2021 that introduced a new ...